16th Nov 2009 08:00
16 November 2009
ABCAM PLC ("Abcam" or "the Company")
Additional Listing
Application has been made to AIM for the admission of 268,359 ordinary shares of 1p each in the Company to trading. These shares, which will rank pari passu in all respects with the existing shares in issue, have been allotted pursuant to the exercise of options by employees of the Company. Admission is expected to become effective on 17 November 2009.
In addition, application has been made to AIM for the block listing of 1,668,456 ordinary shares of 1p each in the Company. These shares will be issued as appropriate, over time, in connection with the following option schemes:
|
28,456 under the Abcam SAYE Scheme |
|
1,000,000 under the Abcam 2005 Share Option Scheme |
|
100,000 under the Abcam plc Share Incentive Plan |
|
40,000 under the Abcam Unapproved Share Option Scheme |
|
100,000 under the Abcam 2009 Company Share Option Plan |
|
400,000 under the Abcam plc Long Term Incentive Plan |
When issued the shares will rank pari passu in all respects with the existing shares in issue. It is expected that the block listing will become effective on 17 November 2009.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
Numis Securities |
+ 44 (0) 207 260 1000 |
|
Michael Meade / Nick Westlake - Nominated Adviser |
|
|
James Black - Corporate Broking |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Stasa Filiplic |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its four operating companies.
Related Shares:
ABC.L